Literature DB >> 30060941

Surgery in ulcerative colitis: When? How?

Gaetano Gallo1, Paulo Gustavo Kotze2, Antonino Spinelli3.   

Abstract

Ulcerative Colitis (UC) is an idiopathic chronically-remitting inflammatory bowel disorder characterized by a contiguous inflammation of the colonic mucosa affecting the rectum that generally extends proximally in a continuous manner through the entire colon. Patients typically experience intermittent exacerbations, with symptoms characterized by bloody diarrhea associated with urgency and tenesmus. The anatomical extent of mucosal involvement is the most important factor determining disease course and is an important predictor of colectomy. The precise etiology of UC is unknown. However, a combination of genetic predisposition and environmental factors seems to have a key role in the development of the disease. UC usually is mildly active but it can be a life-threatening condition because of colonic and systemic complications, and later in the disease course due to the development of colorectal cancer. Interestingly, even if pathogenetic features detected in patients with sporadic CRC can be also found in UC-related colorectal cancer (UC-CRC), this latter is, usually, driven by an inflammation-driven pathway rising from a non-neoplastic inflammatory epithelium to dysplasia to cancer. Thus, a long-term follow-up with colonoscopy surveillance has been recommended. Approximately 15% of UC patients develop an acute attack of severe colitis, and 30% of these patients require colectomy. The initial treatment strategy in UC typically follows the traditional step-up approach. One third of the patients will not respond to steroid therapy and cyclosporine and infliximab are the most common salvage agents employed in these cases in order to avoid emergent surgery. Unfortunately, although a significant short-term benefit have been observed after infliximab treatment, the colectomy rate have remained stable. Surgery in UC depends on the stage of the disease as well as patient's status and is divided into the following settings: urgent, emergent and elective. Despite many efforts the surgical management of UC remains a significant challenge. A multidisciplinary management of UC is key in order to define the best timing and the best procedure for each patient in an individualized basis.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inflammatory bowel disease; Medications; Multidisciplinary management; Surgery; Timing; Ulcerative colitis

Mesh:

Year:  2018        PMID: 30060941     DOI: 10.1016/j.bpg.2018.05.017

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  15 in total

1.  Predictive Value of Procalcitonin in Acute Severe Ulcerative Colitis: Not Quite PerfeCT?

Authors:  Deok Whan Kim; Jeong Min An; Seong Pyo Hong; Ki Baik Hahm
Journal:  Dig Dis Sci       Date:  2019-11       Impact factor: 3.199

2.  Safety and feasibility of repeat laparoscopic colorectal resection: a matched case-control study.

Authors:  Alban Zarzavadjian le Bian; Laurent Genser; Christine Denet; Carlotta Ferretti; Anais Laforest; Jean-Marc Ferraz; Candice Tubbax; Philippe Wind; Brice Gayet; David Fuks
Journal:  Surg Endosc       Date:  2019-07-19       Impact factor: 4.584

3.  Correlation of ulcerative colitis and colorectal cancer: a systematic review and meta-analysis.

Authors:  Yansong Wang; Pu Wang; Lixiang Shao
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 4.  The Management of the Hospitalized Ulcerative Colitis Patient: the Medical-Surgical Conundrum.

Authors:  Michele Carvello; Joseph Watfah; Marcin Włodarczyk; Antonino Spinelli
Journal:  Curr Gastroenterol Rep       Date:  2020-02-10

5.  Spray-Dried Formulation of Epicertin, a Recombinant Cholera Toxin B Subunit Variant That Induces Mucosal Healing.

Authors:  Micaela A Reeves; Joshua M Royal; David A Morris; Jessica M Jurkiewicz; Nobuyuki Matoba; Krystal T Hamorsky
Journal:  Pharmaceutics       Date:  2021-04-18       Impact factor: 6.321

6.  Timing of Surgery to Treat Ulcerative Colitis: An Investigation Focused on Japanese Adults.

Authors:  Saki Yamada; Hitoshi Kameyama; Kaoru Abe; Kana Tanaka; Hidehito Oyanagi; Yosuke Tajima; Masato Nakano; Yoshifumi Shimada; Jun Sakata; Toshifumi Wakai
Journal:  Inflamm Intest Dis       Date:  2020-01-28

7.  In Silico and In Vivo Studies on the Mechanisms of Chinese Medicine Formula (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis.

Authors:  Xiaolu Liu; Yuling Fan; Lipeng Du; Zhigang Mei; Yang Fu
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

8.  PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer.

Authors:  Naoya Ozawa; Takehiko Yokobori; Katsuya Osone; Chika Katayama; Kunihiko Suga; Chika Komine; Yuta Shibasaki; Takuya Shiraishi; Takuhisa Okada; Ryuji Kato; Hiroomi Ogawa; Akihiko Sano; Makoto Sakai; Makoto Sohda; Hitoshi Ojima; Tatsuya Miyazaki; Yoko Motegi; Munenori Ide; Takashi Yao; Hiroyuki Kuwano; Ken Shirabe; Hiroshi Saeki
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

Review 9.  Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review.

Authors:  Chiara Rocchi; Youssef Y Soliman; Marco Massidda; Salvatore F Vadalà di Prampero; Milutin Bulajic; Dario Sorrentino
Journal:  Dig Dis Sci       Date:  2021-06-07       Impact factor: 3.487

10.  Nanogels of a Succinylated Glycol Chitosan-Succinyl Prednisolone Conjugate: Release Behavior, Gastrointestinal Distribution, and Systemic Absorption.

Authors:  Haiyan Zhou; Yuri Ikeuchi-Takahashi; Yoshiyuki Hattori; Hiraku Onishi
Journal:  Int J Mol Sci       Date:  2020-03-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.